Details werden geladen...
Satralizumab Approved for Thyroid Eye Disease
The supplemental indication for satralizumab, already sold for a rare neuroinflammatory disease, is another example of the recent marked growth in approved treatments for thyroid eye disease.
Ähnliche Seiten
Daxdilimab Reduces Disease Activity in Discoid Lupus Study
https://www.medscape.com/viewarticle/phase-2-trial-daxdilimab-reduces-disease-activity-moderate-2026a10010wt
Advancing Cell Therapy for Cardiovascular Disease
https://www.genengnews.com/multimedia/webinars/advancing-cell-therapy-for-cardiovascular-disease/FMT Advances and the Case for Human Connection
https://www.medscape.com/viewarticle/fmt-advances-and-case-human-connection-2026a10010gwFDA Approves New Nonprescription Treatment for Eye Redness
https://www.medscape.com/viewarticle/fda-approves-new-nonprescription-eye-drops-eye-redness-2026a100132f
After 30 years, scientists finally have a drug for a deadly brain disease | ScienceDaily
https://www.sciencedaily.com/releases/2026/10/261007042111.htm